FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

Go back to FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
(NASDAQ: IBRX) Delayed: 8.64 --0 (-0%)
Previous Close $8.64    52 Week High $ 
Open $8.64    52 Week Low $ 
Day High $8.64    P/E N/A 
Day Low $8.64    EPS $ 
Volume 3,064